Protalix BioTherapeutics Files 8-K on Shareholder Vote Matters
Ticker: PLX · Form: 8-K · Filed: Jun 26, 2025 · CIK: 1006281
| Field | Detail |
|---|---|
| Company | Protalix Biotherapeutics, Inc. (PLX) |
| Form Type | 8-K |
| Filed Date | Jun 26, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
Related Tickers: PLX
TL;DR
PLX shareholders are voting on something important, filing today.
AI Summary
On June 26, 2025, Protalix BioTherapeutics, Inc. filed an 8-K report indicating a submission of matters to a vote of security holders. The company, incorporated in Delaware, is involved in the biological products industry and is headquartered in Hackensack, NJ.
Why It Matters
This filing signals that Protalix BioTherapeutics is engaging its shareholders on important corporate decisions, which could impact the company's future direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure regarding shareholder votes and does not inherently present new financial or operational risks.
Key Players & Entities
- Protalix BioTherapeutics, Inc. (company) — Registrant
- June 26, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Hackensack, NJ (location) — Business Address
FAQ
What specific matters are being submitted for a vote of security holders?
The filing does not specify the exact matters to be voted on, only that such matters are being submitted.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 26, 2025.
What is Protalix BioTherapeutics, Inc.'s Standard Industrial Classification code?
The SIC code is 2836, for Biological Products (No Diagnostic Substances).
Where is Protalix BioTherapeutics, Inc. headquartered?
The company's business address is 2 University Plaza, Suite 100, Hackensack, NJ 07601.
What is the SEC file number for Protalix BioTherapeutics, Inc.?
The SEC file number is 001-33357.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 26, 2025 regarding Protalix BioTherapeutics, Inc. (PLX).